

March 10, 2017



**DCAT**  
**TOP** ↑  
**Industry**  
**NEWS**

***BUSY WEEK?** Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*



DCAT  
WEEK  
2017




**OPENING DAY**



**HAPPY  
HOUR**



**Patheon**  
A HEALTHIER WORLD. DELIVERED.



[Request an invitation](#)

**1. [FDA, Generics Industry Urge Congress to Reauthorize GDUFA](#)**

The FDA and the Association for Accessible Medicines are calling on Congress to re-authorize the Generic Drug User Fee Amendments (GDUFA), which expires later this year and which sets user fees to supplement generic drug review and inspection costs. [Read More](#)

**2. [Sanofi, AstraZeneca in \\$650-Million mAb Deal](#)**

Sanofi and its vaccines unit, Sanofi Pasteur, have agreed to develop and commercialize a monoclonal antibody for preventing respiratory syncytial virus-associated illness in collaboration with MedImmune, AstraZeneca's biologics research and development arm, in a deal worth up to approximately \$650 million. [Read More](#)

**3. [Merck KGaA Opens Biopharm Production Plant](#)**

Merck KGaA's allergy business, Allergopharma, has opened a new EUR 42 million (\$45 million) biopharmaceutical production facility in Reinbek, Germany for manufacturing products to treat allergies. [Read More](#)

**4. [Apotex Invests \\$184 Million in US Manufacturing Expansion](#)**

Apotex plans to invest \$184 million to expand its US operations, which will include a new research and development center and an advanced manufacturing and packaging facility in Miramar, Florida that will serve as the US headquarters for Apotex Corporation. [Read More](#)

**5. [China's BeiGene to Build \\$320-Million Biomanufacturing Plant](#)**

China's BeiGene, a clinical-stage biopharmaceutical company, has formed a joint venture with the Guangzhou Development District and its affiliate, Guangzhou GET Technology Development, to build a commercial-scale biomanufacturing plant in Guangzhou, China for Chinese yuan renminbi 2.2 billion (\$320 million). [Read More](#)

**6. [Russia OKs Biosimilar to Merck KGaA's Top-Selling MS Drug](#)**

Biocad, a Russian biopharmaceutical company, has received approval from the Ministry of Health of the Russian Federation for a biosimilar of Merck KGaA's multiple sclerosis drug, Rebif (interferon beta-1a), which had 2016 sales of EUR 1.7 billion (\$1.8 billion). [Read More](#)

**7. [GSK to Transfer Costa Rica Manufacturing Operations](#)**

As part of a strategic review of its manufacturing, GlaxoSmithKline announced it is transferring its manufacturing operations in Costa Rica to other facilities in its Latin America network over a period of three years that will end in 2019. [Read More](#)

## 8. [FDA's CDER Outlines Priority Goals for 2017](#)

The FDA's Center for Drug Evaluation and Research (CDER) has outlined priority goals in 2017, which include improved informatics, the implementation of the 21st Century Cures Act, reauthorization of user fees for new drugs, generics, and biosimilars, and evaluating the new drug review process. [Read More](#)

## 9. [Granules Secures Funding for API Plant](#)

Granules India has received approval for \$47.5 million in funding from the International Finance Corporation, a member of the World Bank Group, for expansion projects, including construction of a new active pharmaceutical ingredient facility in Vishakhapatnam, India. [Read More](#)

## 10. [Otsuka to Acquire ADHD Company in \\$250-Million Deal](#)

Otsuka Pharmaceutical has agreed to acquire Neurovance, a clinical-stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADHD) and related disorders, in a \$250-million deal. [Read More](#)

## [Emerging Pharma: Boom or Bust for Pharma Partnering and Suppliers?](#)

Emerging pharma companies are an important source of innovation for the pharmaceutical industry, but how is this sector performing, and what are the opportunities for partnering for larger pharma companies and for suppliers, CDMOs, and CMOs? The DCAT Week education program, [Emerging Pharma: Market Overview, Innovation in Project Management, and CMC Readiness](#), provides the latest on financing trends and partnerships into this sector, how investors rank manufacturing in their valuations, and first-hand insight from pharma companies and suppliers in project management. [Read More](#)

## About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [mailmanager@dcatt.org](mailto:mailmanager@dcatt.org)